期刊
CARDIOVASCULAR RESEARCH
卷 105, 期 1, 页码 96-106出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvu237
关键词
Hypercholesterolaemia; Neuropeptides; Hind limb ischaemia; Myocardial infarction; Therapeutic angiogenesis
资金
- Austrian Science Fund [P-21021-B05]
Aims Hypercholesterolaemia is a major risk factor for cardiovascular diseases and has been shown to influence angiogenesis in the hind limb ischaemia (HLI) model. The impaired up-regulation of angiogenic factors seems to be one of the underlying mechanisms for reduced vessel formation. Since we found that secretoneurin (SN) is up-regulated in hypoxic skeletal muscle cells and exerts beneficial effects in myocardial and HLI, we hypothesized that SN therapy might improve neovascularization in hypercholesterolaemic Apo E-/- (Apo E knockout) mice suffering from an impaired vascular response. Methods and results For in vitro experiments, endothelial cells (ECs) were incubated with oxidized low-density lipoprotein (oxLDL) to mimic hypercholesterolaemia. EC function was impaired by oxLDL, but SN induced EC proliferation and in vitro tube formation under these conditions. In the HLI model, injection of SN plasmid resulted in a significant better outcome regarding blood flow recovery, amputation rate, and vessel density. In the myocardial infarction (MI) model, the SN group showed improvement in cardiac parameters. Aortic plaque area was not influenced by local SN injection. Interestingly, SN-induced recruitment of angiogenic monocytic cells was abolished under hypercholesterolaemia. Conclusions SN gene therapy exerts beneficial effects in cardiovascular animal models in Apo E-/- mice without influencing atherosclerosis and might qualify as a promising therapy for cardiovascular disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据